Bristol-Myers Squibb to Buy Amylin for $5.3 Billion

Bristol-Myers Squibb to Buy Amylin for $5.3 Billion: Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, and has reached a $3.4 billion deal with AstraZeneca.